PAMELA SUMMERS: Open Payments
NPI 1982240776 · ATHENS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,260 in 118 payments from 13 companies in 2025. Trend: 2023 $2,404 · 2024 $2,589 · 2025 $2,260
Food & beverage: $2,260
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 21 | $365 |
| Vanda Pharmaceuticals Inc. | 14 | $353 |
| Neurocrine BioSciences, Inc. | 13 | $333 |
| ABBVIE INC. | 21 | $271 |
| E.R. Squibb & Sons, L.L.C. | 15 | $244 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $198 |
| Alkermes, Inc. | 11 | $180 |
| Otsuka America Pharmaceutical, Inc. | 5 | $138 |
| Lundbeck LLC | 3 | $73 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
Products named: FANAPT, INGREZZA, UZEDY, VRAYLAR, COBENFY, CAPLYTA, ARISTADA, REXULTI.
Industry payments across TX — which companies pay providers there.
